Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic
S.K. Mahil, Zenas Z N Yiu, K.J. Mason, Nick Dand, Bola Coker, Dmitri Wall, G. Fletcher, Angela L. Bosma, Francesca Capon, Lars Iversen, Sinéad Langan, Paola Di Meglio, Annelie H. Musters, David Prieto‐Merino, Teresa Tsakok, Richard B. Warren, Carsten Flohr, Phyllis I. Spuls, C.E.M. Griffiths, Jessica L. Barker, Alan D. Irvine, Catherine Smith, the Secure‐AD and PsoProtect study groups
Abstract
We read with interest the article in the BJD by Gambichler and colleagues 1 about a decline of programmed death (PD)-1 + circulating T regulatory cells (Tregs) predicting clinical outcome in anti-PD-1 therapy. The study highlights the potential and importance of immune monitoring in anti-PD-1 checkpoint therapy in malignant melanoma.
Topics & Concepts
MedicineAntibodyImmunologyDiscontinuationNatalizumabBlocking antibodyPopulationTherapeutic approachDiseaseInternal medicineMultiple sclerosisEnvironmental healthDermatology and Skin DiseasesPsoriasis: Treatment and PathogenesisAsthma and respiratory diseases